Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 85Lymphoma, Follicular 53Lymphoma 50Lymphoma, Non-Hodgkin 47Lymphoma, Mantle-Cell 45Lymphoma, B-Cell, Marginal Zone 45Leukemia, Lymphocytic, Chronic, B-Cell 40Lymphoma, B-Cell 31Recurrence 20Burkitt Lymphoma 20Waldenstrom Macroglobulinemia 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasms 16Leukemia 11Leukemia, Hairy Cell 7Lymphoproliferative Disorders 5Hodgkin Disease 5Hematologic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Dendritic Cell Sarcoma, Interdigitating 4Neoplasm, Residual 3Lymphoma, AIDS-Related 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Epstein-Barr Virus Infections 3beta-Thalassemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

varlilumab 1liposomal doxorubicin 1etoposide phosphate 1Vincristine 1Ultrasonography 1Rituximab 1Prednisone 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Etoposide 1Endoscopy 1Electrocardiography 1Echocardiography 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Bronchoscopy 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Primary Effusion × Rituximab × 1 year × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡